Although we cannot be certain that in a large study the difference in serious adverse events may be significant, we think this is unlikely because previous systematic reviews of combination DMARD therapies[35] and treat to target trials [8] showed no increases in adverse events in many of these trials.
← all excerpts
The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial.
1
—
—